Chronic PainPhase 2NCT07874620
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
A Phase 2 study testing Cebranopadol in people with Chronic Pain and Pain, run by Adneuris Therapeutics, Inc. at 2 sites in United States.
Trial summary
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Chronic Pain, Pain, Opioid Withdrawal (Disorder)
- What is being tested?
- Cebranopadol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- 2 sitesUnited States
- Study dates
- Oct 2026to Jun 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults 18-65 years with BMI 18.0-40.0 kg/m² and weight ≥50 kg.
- Chronic daily pain for ≥6 months due to chronic low back pain, hip/knee osteoarthritis, or painful peripheral neuropathy.
- Prescribed opioid use ≥5 days/week for ≥3 months within the prior 6 months, generally 50-90 MME/day; >90 MME/day may be allowed with Sponsor/designee approval.
- Generally in good health and able to comply with study procedures, including opioid withdrawal and inpatient confinement.
- Meet protocol-specified reproductive and contraception requirements.
- Able to provide informed consent and complete study assessments in English.
- Physical opioid dependence confirmed by protocol-defined COWS and/or SOWS criteria before randomization.
Who cannot join
- Clinically significant medical or psychiatric condition that could compromise participant safety or study validity.
- Protocol-specified excluded pain, neurologic, spinal, infectious, or neoplasm-related conditions.
- QTcF >450 ms in males or >470 ms in females, other torsade de pointes risk factors, or use of QT-prolonging medications.
- Substance use disorder other than opioid, nicotine, or caffeine use disorder, or positive testing for prohibited drugs/alcohol, subject to the protocol-specified cannabinoid exception.
- Positive HIV, hepatitis B surface antigen, or hepatitis C antibody test.
- Suicidal ideation or active suicidality within the past 2 years.
Show all 11Show fewer
- Use of prohibited medications or inability to meet protocol-specified medication washout requirements.
- Pregnant or breastfeeding or planning pregnancy within 30 days after the last study-drug dose.
- Significant adverse reaction to naloxone or related opioids/opioid antagonists.
- Unable to undergo IV catheter placement or otherwise considered unsuitable or unlikely to comply with the protocol.
- Legal, employment, or other circumstances that could interfere with study participation or compliance.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
00113
Houston, Texas, 77043
- Recruiting
001127
North Canton, Ohio, 44702
About this study
Official title: A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.
Read the detailed description
Participants will complete outpatient screening followed by an inpatient treatment period and a safety follow-up telephone call. Within 30 days of initiating screening, participants will be admitted to the clinical research site.
Their current prescribed opioid will be withheld after the scheduled morning dose on Day -1, and withdrawal signs and symptoms will be assessed using the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opioid Withdrawal Scale (SOWS) to confirm physical dependence. Participants meeting the predefined withdrawal criteria will resume their prescribed opioid as specified in the protocol and will subsequently be randomized on Day 1. Eligible participants will be randomized 1:1:1, stratified by current prescribed daily opioid regimen (50-75 morphine milligram equivalents [MME] versus >=76 MME), to cebranopadol 400 micrograms in the morning plus 200 micrograms in the evening, cebranopadol 400 micrograms twice daily, or matching placebo twice daily. Study drug is administered every 12 hours for 48 hours. Participants remain inpatient during treatment and undergo withdrawal, pain, safety, and pharmacokinetic assessments. Rescue medication is available according to protocol-defined criteria. Participants may resume their current prescribed opioid at least 12 hours after the final study-drug dose and are monitored until discharge on Day 4. A safety follow-up telephone call occurs on Day 7 (+/-2 days) after the last study-drug administration
- Conditions
- Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
- Being tested
- Cebranopadol, Placebo
- Keywords
- cebranopadol, opioid withdrawal;, physical dependence;, chronic pain;, Clinical Opiate Withdrawal Scale, COWS, Subjective Opioid Withdrawal Scale, SOWS Opioid use disorder, Subject Opioid Withdrawal scale
- Medical subject headings
- Chronic Pain, Pain, Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CebranopadolDrug
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
CebranopadolDrug
Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.
PlaceboDrug
Administration orally twice daily on Day 1 and 2.
| Study group | Role | What they receive |
|---|---|---|
| Cebranopadol 600 micrograms/day | Experimental | Cebranopadol 400 micrograms orally in the morning and 200 micrograms orally in the evening on Day 1 and 2; final dose on the evening of Day 2 Receives: Drug: Cebranopadol |
| Cebranopadol 800 micrograms/day | Experimental | Cebranopadol 400 micrograms orally twice daily on Day 1 and 2; Final dose on the evening of Day 2. Receives: Drug: Cebranopadol |
| Placebo Comparator | Placebo comparator | Matching placebo orally twice daily on Day 1 and 2 days; Final dose on the evening of Day 2. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hours
Maximum (peak) COWS total score observed during the 48-hour assessment period. after the first study drug dose, using the protocol-specified adjustment for rescue medication. The COWS is an 11-item clinician-rated scale used to assess opioid withdrawal signs and symptoms. Total scores range from 0 to 48, with higher scores indicating greater withdrawal severity.
Measured: From first study-drug administration through 48 hours after the first dose]
Secondary outcomes (12)
Area under the curve of COWS Total Score from 0 to 48 hours (AUC0-48)
Area under the curve (AUC) of COWS total score-time curve from 0 to 48 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication. COWS total scores range from 0 to 48, with higher scores indicating greater withdrawal severity.
Measured: From first study-drug administration through 48 hours after the first dose.
Proportion of Participants Meeting the COWS Responder Criteria
Proportion of participants meeting the protocol-defined COWS responder criteria based on average COWS total score and absence of opioid rescue medication through 24 hours.
A responder is defined as having at least 30 percent improvement and/or a COWS total score of 5 or less and/or transition to a lower withdrawal severity category from baseline, without opioid rescue medication through 24 hours.
Measured: From first study-drug administration through 24 hours after the first dose
Maximum Change From Baseline in COWS Total Score by Dosing Day.
Maximum change from baseline in COWS total score by dosing day during Day 1, Day 2.
Measured: Baseline- From first study-drug administration through 72 hours after the first dose
Area Under the Curve of COWS Total Score From 0 to 24 Hours (AUC0-24) COWS Total Score AUC0-24and From 0 to 72 Hours (AUC0-72).
Area under the curve (AUC) of COWS total scores, through 24 hours; and 72 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication.
Measured: 0-24 hours and 0-72 hours after first study-drug administration
Maximum Subjective Opioid Withdrawal Scale (SOWS) Total Score.
Subjective Opioid Withdrawal Scale total score assessed using Emax, maximum change from baseline by dosing day, and area-under-the-curve summaries.
The SOWS is a participant-reported measure of opioid withdrawal symptoms. Total scores range from 0 to 64, with higher scores indicating greater withdrawal severity.
Measured: Through 72 hours after first study-drug administration]
Participants Receiving Rescue Medication
Proportion of participants who receive protocol-permitted rescue medication for withdrawal signs and symptoms.
Measured: Through the inpatient assessment period, up to 72 hours after first study-drug administration
Time to First Rescue Medication for Withdrawal
Time from first study-drug administration to first administration of protocol permitted rescue medication to manage withdrawal symptoms
Measured: Up to 72 hours after first study-drug administration
Opioid Rescue Medication Use
Number of opioid rescue medication doses and total opioid rescue medication use expressed in morphine milligram equivalents (MME).
Measured: Up to 72 hours after first study-drug administration]
Area Under the Curve of "Pain Right Now" Numeric Pain Rating Scale Score From 0 to 48 Hours (AUC0-48)
Area under the curve for of "Pain Right Now" Numerical Pain Rating Scale (NPRS) pain 'right now' scores from 0 to 48 hours after the first study drug dose, using the protocol-specified adjustment for rescue medication. NPRS scores range from 0 (no pain) to 10 (worst possible pain).
Measured: 0 to 48 hours after first study-drug administration
Proportion of Participants With at Least a 2-Point Improvement from Baseline in Average 24-Hour Pain.
Percentage of participants with at least a 2-point improvement from baseline in the NPRS rating of average pain during the previous 24 hours.
Measured: 0 to 72 hours after first study-drug administration
Change From Baseline in Average/Worst/Least Pain During the Previous 24 Hours
Change from baseline in participant-reported Average/Worst/Least pain during the previous 24 hours on NPRS.
Measured: 0 to 72 hours after first study drug administration
Non-Opioid Rescue Medication Use
Number of non-opioid rescue medication doses and total non-opioid rescue medication use summarized by medication type.
Measured: Up to 72 hours after first study-drug administration]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2026
- Study startOct 2026 (estimated)
- Primary completionMar 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Chronic PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized in a 1:1:1 ratio to two cebranopadol dose regimens or matching placebo.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Adneuris Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Khyati Mehta, Study director, Adneuris Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07874620
- Sponsor's protocol ID
- TRN-228-201
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011 Oct;152(10):2399-2404. doi: 10.1016/j.pain.2011.07.005.
PubMed 21856077Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016.
PubMed 21621130Lofwall MR, Walsh SL, Bigelow GE, Strain EC. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl). 2007 Oct;194(3):381-93. doi: 10.1007/s00213-007-0847-3. Epub 2007 Jul 1.
PubMed 17605004Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016 Jul 1;164:143-150. doi: 10.1016/j.drugalcdep.2016.05.002. Epub 2016 May 10.
PubMed 27234658Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004 Nov;99(11):1439-49. doi: 10.1111/j.1360-0443.2004.00834.x.
PubMed 15500597Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. doi: 10.1080/02791072.2003.10400007.
PubMed 12924748
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids
- ClinicalTrials.gov ID
- NCT07874620
- Acronym / sponsor ID
- TRN-228-201
- Conditions
- Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
- Keywords
- cebranopadol, opioid withdrawal;, physical dependence;, chronic pain;, Clinical Opiate Withdrawal Scale, COWS, Subjective Opioid Withdrawal Scale, SOWS Opioid use disorder
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Adneuris Therapeutics, Inc.Industry (pharma, biotech, devices)
- Study start
- Oct 2026 (estimated)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 15 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.
Detailed description
Participants will complete outpatient screening followed by an inpatient treatment period and a safety follow-up telephone call. Within 30 days of initiating screening, participants will be admitted to the clinical research site.
Their current prescribed opioid will be withheld after the scheduled morning dose on Day -1, and withdrawal signs and symptoms will be assessed using the Clinical Opiate Withdrawal Scale (COWS) and Subjective Opioid Withdrawal Scale (SOWS) to confirm physical dependence. Participants meeting the predefined withdrawal criteria will resume their prescribed opioid as specified in the protocol and will subsequently be randomized on Day 1. Eligible participants will be randomized 1:1:1, stratified by current prescribed daily opioid regimen (50-75 morphine milligram equivalents [MME] versus >=76 MME), to cebranopadol 400 micrograms in the morning plus 200 micrograms in the evening, cebranopadol 400 micrograms twice daily, or matching placebo twice daily. Study drug is administered every 12 hours for 48 hours. Participants remain inpatient during treatment and undergo withdrawal, pain, safety, and pharmacokinetic assessments. Rescue medication is available according to protocol-defined criteria. Participants may resume their current prescribed opioid at least 12 hours after the final study-drug dose and are monitored until discharge on Day 4. A safety follow-up telephone call occurs on Day 7 (+/-2 days) after the last study-drug administration
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- Participants are randomized in a 1:1:1 ratio to two cebranopadol dose regimens or matching placebo.
| Arm | Type | Receives |
|---|---|---|
| Cebranopadol 600 micrograms/day | Experimental | Drug: CebranopadolCebranopadol 400 micrograms orally in the morning and 200 micrograms orally in the evening on Day 1 and 2; final dose on the evening of Day 2 |
| Cebranopadol 800 micrograms/day | Experimental | Drug: CebranopadolCebranopadol 400 micrograms orally twice daily on Day 1 and 2; Final dose on the evening of Day 2. |
| Placebo Comparator | Placebo comparator | Drug: PlaceboMatching placebo orally twice daily on Day 1 and 2 days; Final dose on the evening of Day 2. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults 18-65 years with BMI 18.0-40.0 kg/m² and weight ≥50 kg.
- Chronic daily pain for ≥6 months due to chronic low back pain, hip/knee osteoarthritis, or painful peripheral neuropathy.
- Prescribed opioid use ≥5 days/week for ≥3 months within the prior 6 months, generally 50-90 MME/day; >90 MME/day may be allowed with Sponsor/designee approval.
- Generally in good health and able to comply with study procedures, including opioid withdrawal and inpatient confinement.
- Meet protocol-specified reproductive and contraception requirements.
Key exclusion criteria (11 listed)
- Clinically significant medical or psychiatric condition that could compromise participant safety or study validity.
- Protocol-specified excluded pain, neurologic, spinal, infectious, or neoplasm-related conditions.
- QTcF >450 ms in males or >470 ms in females, other torsade de pointes risk factors, or use of QT-prolonging medications.
- Substance use disorder other than opioid, nicotine, or caffeine use disorder, or positive testing for prohibited drugs/alcohol, subject to the protocol-specified cannabinoid exception.
- Positive HIV, hepatitis B surface antigen, or hepatitis C antibody test.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CebranopadolAdministration orally twice daily on Days 1 and 2 and according to the assigned regimen. | Drug | Cebranopadol 600 micrograms/day |
| CebranopadolAdministration orally twice daily on Days 1 and 2 and according to the assigned regimen. | Drug | Cebranopadol 800 micrograms/day |
| PlaceboAdministration orally twice daily on Day 1 and 2. | Drug | Placebo Comparator |
Primary outcome
Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hours
Time frame: From first study-drug administration through 48 hours after the first dose]
Maximum (peak) COWS total score observed during the 48-hour assessment period. after the first study drug dose, using the protocol-specified adjustment for rescue medication. The COWS is an 11-item clinician-rated scale used to assess opioid withdrawal signs and symptoms. Total scores range from 0 to 48, with higher scores indicating greater withdrawal severity.
12 secondary outcomes
Area under the curve of COWS Total Score from 0 to 48 hours (AUC0-48)
Time frame: From first study-drug administration through 48 hours after the first dose.
Proportion of Participants Meeting the COWS Responder Criteria
Time frame: From first study-drug administration through 24 hours after the first dose
Maximum Change From Baseline in COWS Total Score by Dosing Day.
Time frame: Baseline- From first study-drug administration through 72 hours after the first dose
Area Under the Curve of COWS Total Score From 0 to 24 Hours (AUC0-24) COWS Total Score AUC0-24and From 0 to 72 Hours (AUC0-72).
Time frame: 0-24 hours and 0-72 hours after first study-drug administration
Maximum Subjective Opioid Withdrawal Scale (SOWS) Total Score.
Time frame: Through 72 hours after first study-drug administration]
Participants Receiving Rescue Medication
Time frame: Through the inpatient assessment period, up to 72 hours after first study-drug administration
Time to First Rescue Medication for Withdrawal
Time frame: Up to 72 hours after first study-drug administration
Opioid Rescue Medication Use
Time frame: Up to 72 hours after first study-drug administration]
Area Under the Curve of "Pain Right Now" Numeric Pain Rating Scale Score From 0 to 48 Hours (AUC0-48)
Time frame: 0 to 48 hours after first study-drug administration
Proportion of Participants With at Least a 2-Point Improvement from Baseline in Average 24-Hour Pain.
Time frame: 0 to 72 hours after first study-drug administration
Change From Baseline in Average/Worst/Least Pain During the Previous 24 Hours
Time frame: 0 to 72 hours after first study drug administration
Non-Opioid Rescue Medication Use
Time frame: Up to 72 hours after first study-drug administration]
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Background: PubMed 21856077Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011 Oct;152(10):2399-2404. doi: 10.1016/j.pain.2011.07.005.
- Background: PubMed 21621130Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016.
- Background: PubMed 17605004Lofwall MR, Walsh SL, Bigelow GE, Strain EC. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl). 2007 Oct;194(3):381-93. doi: 10.1007/s00213-007-0847-3. Epub 2007 Jul 1.
- Background: PubMed 27234658Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016 Jul 1;164:143-150. doi: 10.1016/j.drugalcdep.2016.05.002. Epub 2016 May 10.
- Background: PubMed 15500597Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004 Nov;99(11):1439-49. doi: 10.1111/j.1360-0443.2004.00834.x.
- Background: PubMed 12924748Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9. doi: 10.1080/02791072.2003.10400007.
Related trials for Chronic Pain
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Khyati Mehta study director
Adneuris Therapeutics
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cebranopadol in people with Chronic Pain and Pain, run by Adneuris Therapeutics, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Director Adneuris Therapeutics (732-940-2800, clinicaltrials@trispharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hours (time frame: From first study-drug administration through 48 hours after the first dose]). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07874620, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.